Lifeboat Foundation

When researchers fed mosquitoes a drug used to treat people for obesity, the insects were less interested in hunting for their next human meal ticket. Karen Hopkin reports.

Full Transcript

Believe it or not, mosquitoes don’t bite out of spite. Female mosquitoes of the species Aedes aegypti need the nutrients present in your plasma to ensure the proper development of their eggs. And though their thirst may seem unquenchable, the ladies actually take time to savor your blood once they’ve sipped their fill.

Continue reading “Human Diet Drugs Kill Mosquitoes’ Appetite Too” »

A biomedical device designed to lure tumour cells out of the brain Pied Piper-style has been awarded specialist breakthrough status by the US Food and Drug Administration (FDA). Following successful trials in rats, the device, dubbed a ‘tumour monorail’, has been put on the fast track for human trials by the FDA.

Cancer cells are, in some respects, impressive: They can grow relentlessly, sidestep the aging process by becoming immortal, and evade the immune system’s persistent attacks. But in the process of acquiring such superpowers, the cells must occasionally relinquish other, more mundane skills—including the ability to produce certain nutrients.

Researchers at The Rockefeller University now announce the discovery of a rare tumor type that is unable to synthesize cholesterol, a molecule without which cells can’t survive.

“These cells become dependent on taking up cholesterol from their environment, and we can use this dependency to design therapies that block cholesterol uptake,” says Kivanç Birsoy, the Chapman Perelman Assistant Professor, who reports the findings in Nature.

Continue reading “Researchers discover a weakness in a rare cancer that could be exploited with drugs” »

Scientists at the University of Virginia School of Medicine have identified a potential explanation for the mysterious death of specific brain cells seen in Alzheimer’s, Parkinson’s and other neurodegenerative diseases.

The new research suggests that the cells may die because of naturally occurring gene variation in brain cells that were, until recently, assumed to be genetically identical. This variation – called “somatic mosaicism” – could explain why neurons in the temporal lobe are the first to die in Alzheimer’s, for example, and why dopaminergic neurons are the first to die in Parkinson’s.

“This has been a big open question in neuroscience, particularly in various neurodegenerative diseases,” said neuroscientist Michael McConnell of UVA’s Center for Brain Immunology and Glia, or BIG. “What is this selective vulnerability? What underlies it? And so now, with our work, the hypotheses moving forward are that it could be that different regions of the brain actually have a different garden of these [variations] in young individuals and that sets up different regions for decline later in life.”

Continue reading “Brain discovery may explain mysterious cell death in Alzheimer’s, Parkinson’s” »

The so-called “zombie disease” has been reported in deer, elk, and moose across 24 US states, according to a new warning by the US Centers for Disease Control and Prevention (CDC).

As of January 2019, at least 251 counties across the US, from northern Montana to southern Texas, have reported CWD in free-ranging cervids, members of the deer family. Farther afield, there are similar concerns for reindeer in Norway, Finland, and, to a lesser extent, South Korea.

Scientifically known as chronic wasting disease (CWD), the contagious neurological disease gets its sensational nickname because of its effect on the brain of cervids, including North American elk or wapiti, red deer, mule deer, black-tailed deer, white-tailed deer, sika deer, reindeer, and moose. Deer that have been struck with the disease suffer from drastic weight loss, abnormal behavior, stumbling, drooling, lack of coordination, aggression, excessive thirst, and a fear of others.

Continue reading “The ‘Zombie Deer Virus’ Has Hit 24 US States” »

It’s like “The Magic School Bus.”

An experimental drug that bolsters ailing brain cells has raised hopes of a treatment for memory loss, poor decision making and other mental impairments that often strike in old age.

The drug could be taken as a daily pill by over-55s if clinical trials, which are expected to start within two years, show that the medicine is safe and effective at preventing memory lapses.

Tests in the lab showed that old animals had far better memory skills half an hour after receiving the drug. After two months on the treatment, brain cells which had shrunk in the animals had grown back, scientists found.

Continue reading “New drug raises hopes of reversing memory loss in old age” »

But scientists will have to prove the technique is safe first before any human trials.

Over the course of three weeks, the patients took nine doses of a leukemia drug called dasatinib and quercetin, a supplement. By the end of the trial, the patients were reportedly able to walk farther than they could previously in the same amount of time and other signs of improved well being — all without any serious side effects.

“Though small, this pilot study marks a major breakthrough in how we treat age-related diseases such as IPF,” researcher Jamie Justice said in a press release. “Here, we’ve therapeutically targeted a fundamental biological hallmark of aging that is implicated in IPF, and we show early but promising results for the first time in human patients.”